Mitral valve reconstruction and replacement for moderate to severe ischemic mitral regurgitation: comparison of midterm outcome and complications
10.3760/cma.j.issn.1001-4497.2010.02.009
- VernacularTitle:慢性中重度缺血陛二尖瓣关闭不全的外科治疗及中期随访
- Author:
Xuefeng QIU
;
Nianguo DONG
;
Zongquan SUN
;
Shiliang XIAO
;
Kailun ZHANG
;
Xinling DU
;
Xionggang JIANG
;
Wei SU
- Publication Type:Journal Article
- Keywords:
Mitral valve insufficiency;
Myocardial ischemia;
Coronary artery bypass
- From:
Chinese Journal of Thoracic and Cardiovascular Surgery
2010;26(2):95-98
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the results of mitral valve reconstruction and replacement as treatments for moderate to severe ischemic mitral regurgitation(IMR), and report the mid-term outcome. Methods From June 2002 to May 2008, 83 pa-tients with moderate IMR(35 cases) and severe IMR (48 cases) underwent coronary artery bypass grafting(CABG) combined with mitral valvuloplasty (MVP) (n = 43) or mitral valve replacement (MVR) (n = 40). There were 49 males and 34 females with a mean age of (59.3±7.5) years(51 -77years). The procedures of MVP included annuloplasty with a Dacron or autologous per-icardium ring in 21cases, commissural annuloplasty in 9, quadrangular resection of the posterior leaflet in 9 and using St. Jude mitral annuloplasty ring in 4. In the cases underwent MVR, 28 patients received mechanical prostheses and 12 received biopros-theses. Results 30-day mortality rate was 2.3% for MVP and 5.0% for MVR (P >0.05). The 30-day complication rate was similar for the 2 groups but mechanical ventilation time was longer for MVR patients. Mild MR ocurred in 6 patients with MVP (P <0.05). Sevonty-six patients were followed by outpatient department visit or telephone for (20.2 ± 4.9) months (3 - 60 months). During the follow-up period, 7 patients with MVP had mild insufficiency but free off etber complications. All the valve prothesis functioned well. However, 3 cases had thromboembolic complications and 7 late deaths were recorded in MVR group. Five-year complication-free survival rate was 90% for MVP group and 61% for MVR. Conclusion MVP resulted in excellent durability and provided significant mid-term survival benefit over MVR. MVP should be the first choice for patients with chronic IMR.
